Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Combined With Chemotherapy for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
NCT03224221Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Mar 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by First Affiliated Hospital of Anhui Medical University. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03224221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03224221.